STOCK TITAN
  1. Home
  2. Sec-filings
  3. PASG
  4. [Form 4] Passage BIO, Inc. Insider Trading Activity

Director Sondhi Dolan receives 10,539 Passage BIO (PASG) stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Passage BIO, Inc. director Sondhi Dolan received a grant of stock options covering 10,539 shares of common stock. The options have an exercise price of $5.0800 per share and expire on May 19, 2036. Following this grant, Dolan holds options for 10,539 shares directly.

The stock option vests in full on the earlier of the one-year anniversary of the May 19, 2026 grant date or the company’s 2027 annual meeting of stockholders, as long as Dolan continues serving the company through that time.

Positive

  • None.

Negative

  • None.
Insider Sondhi Dolan
Role null
Type Security Shares Price Value
Grant/Award Director Stock Option (right to buy) 10,539 $0.00 --
Holdings After Transaction: Director Stock Option (right to buy) — 10,539 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 10,539 shares Director stock option underlying common stock
Exercise price $5.0800 per share Director stock option strike price
Expiration date May 19, 2036 Option term endpoint
Post-grant option holdings 10,539 shares Total derivative securities following transaction
Director Stock Option (right to buy) financial
"security_title: "Director Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "5.0800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-05-19T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vests in full financial
"The stock option vests in full on the earlier of..."
Annual Meeting of its stockholders financial
"the date of the issuer's 2027 Annual Meeting of its stockholders"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sondhi Dolan
(Last)(First)(Middle)
ONE COMMERCE SQUARE
2005 MARKET STREET, 39TH FLOOR
(Street)
PHILADELPHIA PENNSYLVANIA 19103
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Passage BIO, Inc. [ PASG ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Director Stock Option (right to buy)$5.0805/19/2026A10,539 (1)05/19/2036Common Stock10,539$010,539D
Explanation of Responses:
1. The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
/s/ Kathleen Borthwick, Attorney-in-Fact05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Passage BIO (PASG) director Sondhi Dolan report on this Form 4?

Director Sondhi Dolan reported receiving a stock option grant for 10,539 shares of Passage BIO common stock. This is a compensation-related award, not an open-market trade, and reflects standard equity incentives for board service.

What are the key terms of Sondhi Dolan’s Passage BIO (PASG) stock option grant?

The grant covers 10,539 underlying common shares with an exercise price of $5.0800 per share. The option expires on May 19, 2036, giving Dolan a long-dated right to buy Passage BIO stock at that fixed price.

How and when do Sondhi Dolan’s Passage BIO (PASG) options vest?

The option vests in full on the earlier of the one-year anniversary of the May 19, 2026 grant date or the company’s 2027 annual stockholder meeting, provided Dolan remains in continuous service to Passage BIO through that date.

Is Sondhi Dolan buying or selling Passage BIO (PASG) shares in this filing?

This filing reflects an acquisition of stock options as a grant, not a market purchase or sale of shares. No open-market buying or selling occurred; it documents a compensation award to a Passage BIO director.

How many Passage BIO (PASG) options does Sondhi Dolan hold after this grant?

After this transaction, Sondhi Dolan directly holds stock options covering 10,539 shares of Passage BIO common stock. The Form 4 shows this as the total derivative holdings following the reported grant.